Search

everythinglearnresearchcommunity

for

Search:↓

Reporter characteristics affect detection of hair loss from cancer therapy.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Cancer treatments often cause hair loss, and more research is needed to prevent and treat it.

Some side effects of breast cancer chemotherapy, like neuropathy and nail loss, can last long after treatment.

CK 5/6 expression in breast cancer is linked to negative hormone receptor status and higher tumor grade.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Chemotherapy often causes skin, nail, and hair side effects, significantly impacting quality of life.

Scalp cooling can prevent hair loss in 65% of chemotherapy patients, especially effective in breast cancer patients and certain chemotherapy types.

St. John's wort skin oil may increase skin damage risk during radiotherapy.

A woman with low thyroid function did not lose her hair during chemotherapy, possibly because her hair follicles were less affected by the treatment.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

Core symptoms in breast cancer chemotherapy remain stable, aiding targeted interventions.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Scalp hypothermia can prevent chemotherapy-induced hair loss but is not suitable for all patients, and more research is needed to improve prevention methods.

Chemotherapy and radiotherapy can cause skin side effects like rashes, hair loss, and nail changes, which are usually managed with conservative treatments.

Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.

Combining scalp cooling with a special lotion helps prevent severe hair loss in breast cancer patients undergoing chemotherapy.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

IGRT resulted in lower acute toxicity for stage III prostate cancer patients.

Scalp cooling can help prevent chemotherapy-induced hair loss with a 50-90% success rate and is safe for patients.